1. **(Canceled)**

2. **(Currently Amended)** A compound of Formula I

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein:

D is -NH-C(O)-NH-,

A is of the formula: -L-(M-L^1)$_q$, where

L is substituted or unsubstituted phenyl bound directly to D,

L^1 is phenyl or a 5 to 6 membered hetaryl moiety substituted by at least one substituent, -C(O)R_x,

wherein the heteroatoms of said hetaryl moiety consist of nitrogen,

M is oxygen,

q is 1 and

B is a substituted or unsubstituted pyridyl group, a substituted or unsubstituted quinolinyl group or a substituted or unsubstituted isoquinolinyl group,

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;

R_x is NR_aR_b where R_a and R_b are,

a) independently hydrogen~~, or selected from the group consisting of~~ C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from O, N and S, 5-6 membered C_{3-12} cycloalkyl having 0-3 heteroatoms selected from N, S and O, ~~C_{7-24} aralkyl, C_7-C_{24} alkaryl,~~ substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted 5-6 membered C_{3-10} cycloalkyl, having 0-3 heteroatoms selected from N, S and O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from N, S and O, ~~substituted C_{7-24} aralkyl, substituted C_{7-24} alkaryl,~~ where R_a and R_b are a substituted group, they are substituted by halogen up to per halo, hydroxy, C_{1-10} alkyl, 5-6 membered C_{3-12} cycloalkyl having 0-3 heteroatoms selected from O, S and N, C_{3-12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one

of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from N, S and O, C_{1-10} alkoxy, C_{6-12} aryl, halo-substituted C_{1-6} ~~halo-substituted~~ alkyl up to per halo alkyl, halo-substituted C_6-C_{12} ~~halo-substituted~~ aryl up to per halo aryl, halo-substituted 5-6 membered C_3-C_{12} ~~halo-substituted~~ cycloalkyl having 0-3 heteroatoms selected from N, S and O, up to per halo cycloalkyl, halo substituted C_3-C_{12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by heteroatoms selected from N, S and O, up to per halo hetaryl, ~~halo substituted C_7-C_{24} aralkyl up to per halo aralkylhalo substituted C_7-C_{24} alkaryl up to per halo alkaryl~~;

each W is independently ~~selected from the group consisting of~~ -CN, $-CO_2R^7$, $-C(O)NR^7R^7$, $-C(O)-R^7$, $-NO_2$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl ~~having 0-3 heteroatoms selected from O, S and N~~, C_6-C_{14} aryl, ~~C_7-C_{24} alkaryl, C_7-C_{24} aralkyl,~~ C_{3-12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from O, N and S, ~~C_4-C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S,~~ substituted C_1-C_{10} alkyl, substituted C_1-C_{10} alkoxy, substituted C_2-C_{10} alkenyl, substituted C_1-C_{10} alkenoyl, substituted C_3-C_{10} cycloalkyl ~~having 0-3 heteroatoms selected from O, N and S,~~ substituted C_6-C_{12} aryl [[~~,~~]] or substituted C_3-C_{12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from O, N and S, ~~substituted C_7-C_{24} aralkyl, substituted C_7-C_{24} alkaryl, and substituted C_4-C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S~~;

where W is a substituted group, it is substituted by one or more substituents which are each, independently, -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NR^7R^7$, $-NO_2$, $-NR^7C(O)R^7$, $-NR^7C(O)OR^7$ or halogen,

each R^7 is independently ~~selected from~~ H, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl ~~having 0-3 heteroatoms selected from O, S and N,~~

C_6-C_{14} aryl, C_3-C_{12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from O, N and S, ~~C_7-C_{14} alkaryl, C_7-C_{24} aralkyl, C_4-C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S,~~ up to per-halosubstituted C_3-C_{12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from O, N and S, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl ~~having 0-3 heteroatoms selected form O, N and S,~~ or up to per-halosubstituted C_6-C_{14} aryl ~~, up to per-halosubstituted C_7-C_{24} aralkyl, up to per-halosubstituted C_7-C_{24} alkaryl, and up to per-halosubstituted C_4-C_{23} alkheteroaryl; and~~

~~each Z is independently selected from the group consisting of -CN, $-CO_2R^7$, $-C(O)R^7$, $-C(O)NR^7R^7$, $-NO_2$, $-OR^7$, $-SR^7$ $-NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, C_6-C_{14} aryl, C_3-C_{13} hetaryl having 1-3 heteroatoms selected from O, N and S, C_7-C_{24} alkaryl, C_7-C_{24} aralkyl, C_4-C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C_1-C_{10} alkyl, substituted C_1-C_{10} alkoxy, substituted C_2-C_{10} alkenyl, substituted C_1-C_{10} alkenoyl, substituted C_3-C_{10} cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C_6-C_{12} aryl, substituted C_7-C_{24} alkaryl, substituted C_7-C_{24} aralkyl and substituted C_4-C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S; wherein if Z is a substituted group, the one or more substituents are selected from the group consisting of -CN, $-CO_2R^7$, $-COR^7$, $-C(O)NR^7R^7$, $-OR^7$, $-SR^7$, $-NO_2$, $-NR^7R^7$, $-NR^7C(O)R^7$, and $-NR^7C(O)OR^7$.~~

3. **(Previously Presented)** A compound as in claim 2 wherein L' is phenyl or pyridinyl.

4. **(Currently amended)** A compound as in claim 2 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen ~~Hydrogen~~.

5. **(Currently amended)** A compound of claim 2 wherein B of Formula I is a substituted pyridyl, substituted quinolinyl or substituted isoquinolinyl group substituted 1 to 3 times by ~~1~~ one or more substituents which are each, independently, ~~selected from the group~~

~~consisting of~~ -CN, halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -OH, up to per halo substituted C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkoxy or phenyl substituted by halogen up to per halo.

6. **(Canceled)**

7. **(Canceled)**

8. **(Canceled)**

9. **(Previously Presented)** A compound of claim 2, wherein L^1 is phenyl, pyridinyl or pyrimidinyl.

10. **(Previously Presented)** A compound of claim 5, wherein L^1 is phenyl, pyridinyl or pyrimidinyl.

11. **(Canceled)**

12. **(Currently amended)** A compound of claim 2 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents which are each, independently, ~~selected from the group consisting of~~ C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy or ~~and~~ up to per halo substituted C_1-C_{10} alkoxy.

13. **(Canceled)**

14. **(Currently amended)** A compound of claim 10 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents which are each, independently, ~~selected from the group consisting of~~ C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy ~~and~~ or up to per halo substituted C_1-C_{10} alkoxy.

15. **(Previously Presented)** A compound of claim 2 wherein L^1 is substituted only by $-C(O)R_x$.

16. **(Previously Presented)** A compound of claim 2 wherein L^1 is substituted by $-C(O)R_x$ wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen or C_1 - C_{10} alkyl.

17. (Previously presented) A compound of claim 3 wherein L^1 is substituted by -$C(O)R_x$, wherein R_x is NR_aR_b and R_a and R_b are independently hydrogen or C_1 - C_{10} alkyl .

18. (Previously presented) A compound of claim 10 wherein L^1 is substituted by -$C(O)R_x$, wherein R_x is NR_aR_b and R_a and R_a are independently hydrogen or C_1 - C_{10} alkyl .

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Canceled)

24. (Canceled)

25. (Currently Amended) A compound of claim 2 which is a pharmaceutically acceptable salt of a compound of formula I which is ~~selected from the group consisting of~~

a) a basic salt of an organic acid or inorganic acid which is ~~basic salts of organic acids and inorganic acids selected from the group consisting of~~ hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, or ~~and~~ mandelic acid; and

b) ~~acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations~~ an acid salt of an organic or inorganic base containing a cation which is an alkaline cation, alkaline earth cation, the ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

26. (Canceled)

27. **(Currently amended)** A pharmaceutical composition comprising a compound of Formula I of claim 2 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

28. **(Canceled)**

29. **(Currently Amended)** A method for inhibiting raf kinase in a host ~~the treatment of solid cancers~~ comprising administering to a host in need thereof an effective amount of a compound of Formula I of claim 2.

30. **(Canceled)**

31. **(Canceled)**

32. **(Canceled)**

33. **(Canceled)**

34. **(Currently amended)** A compound which is ~~selected from the group consisting of~~



















or a ~~and~~ pharmaceutically acceptable ~~salts~~ salt thereof.

35. **(Previously presented)** A pharmaceutical composition comprising a compound which is ~~selected from the group consisting of~~

















or a ~~and their~~ pharmaceutically acceptable salt thereof ~~salts~~, and a physiologically acceptable carrier.

36. **(Currently amended)** A method for inhibiting raf kinase in a host ~~the treatment of solid cancers~~, comprising administering to a host in need thereof an effective amount of a compound which is ~~selected from the group consisting of~~



















or a ~~and~~ pharmaceutically acceptable ~~salts~~ salt thereof.

37. **(Currently Amended)** A compound of Formula I:

A - D - B (I)

or a pharmaceutically acceptable salt thereof, wherein

D is -NH-C(O)-NH-,

A is of the formula: -L-(M-L^1)$_q$, where L is phenyl bound directly to D, L^1 is pyridinyl, M is oxygen and q is 1; and

B is a substituted or unsubstituted pyridyl, quinolinyl or isoquinolinyl group,

wherein L^1 is substituted by -C(O)R_x,

R_x is NR_aR_b where R_a and R_b are

independently hydrogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_{3-10} cycloalkyl, C_{2-10} alkenyl, C_{1-10} alkenoyl, C_{6-12} aryl, C_{3-12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from O, N and S, 5-6 membered C_{3-12} cycloalkyl having 0-3 heteroatoms selected from N, S and O, ~~C_{7-24}-aralkyl, C_7-C_{24}-alkaryl,~~ substituted C_{1-10} alkyl, substituted C_{1-10} alkoxy, substituted 5-6 membered C_{3-10} cycloalkyl, having 0-3 heteroatoms selected from N, S and O, substituted C_{6-12} aryl, substituted C_{3-12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from N. S and O, ~~substituted C_{7-24}-aralkyl, substituted C_{7-24}-alkaryl,~~ where R_a and R_b are a substituted group, they are substituted by halogen up to per halo, hydroxy[[$_7$]] or C_{1-10} alkyl; ~~or~~

where B is substituted, L is substituted or L^1 is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and Wn, where n is 0-3;

wherein each W is independently ~~selected from the group consisting of~~ -CN, -CO_2R^7, -C(O)NR^7R^7, -C(O)-R^7, -NO_2, -OR^7, -SR^7, -NR^7R^7, -$NR^7C(O)OR^7$, -$NR^7C(O)R^7$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl ~~having 0-3 heteroatoms selected from O, S and N,~~ C_6-C_{14} aryl, ~~C_7-C_{24}-alkaryl, C_7-C_{24}-aralkyl,~~ C_{3-12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from O, N and S, ~~C_4-C_{23}-alkheteroaryl having 1-3 heteroatoms selected from O, N and S, substituted C_1-C_{10}-alkyl, substituted C_1-C_{10}-alkoxy, substituted C_2-C_{10}-alkenyl, substituted C_1-C_{10}-alkenoyl, substituted C_3-C_{10}-cycloalkyl having 0-3 heteroatoms selected from O, N and S, substituted C_6-C_{12}-aryl, substituted C_{3-12}-hetaryl having 1-3 heteroatoms selected from O, N and S, substituted C_7-C_{24}-aralkyl, substituted C_7-C_{24}-alkaryl, and substituted C_4-C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S,~~ optionally substituted by one

or more substituents which are, independently, ~~selected from the group consisting of~~ -CN, -CO_2R^7, -$C(O)R^7$, -$C(O)NR^7R^7$, -OR^7, -SR^7, -NR^7R^7, -NO_2, -$NR^7C(O)R^7$, -$NR^7C(O)OR^7$ ~~and~~ or halogen up to per-halo; with each R^7 independently ~~selected from~~ H, ~~or~~ C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_2-C_{10} alkenyl, C_1-C_{10} alkenoyl, C_3-C_{10} cycloalkyl ~~having 0-3 heteroatoms selected from O, S and N,~~ C_6-C_{14} aryl, C_{3-12} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from O, N and S, ~~C_7-C_{14} alkaryl, C_7-C_{24} aralkyl, C_4-C_{23} alkheteroaryl having 1-3 heteroatoms selected from O, N and S,~~ up to per-halosubstituted C_3-C_{13} hetaryl which is a 5-12 carbon atom aromatic ring system of 1-3 rings, at least one of which is aromatic, in which 1-3 carbon atoms are replaced by ~~having 1-3~~ heteroatoms selected from O, N and S, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl ~~having 0-3 heteroatoms selected form O, N and S,~~ or up to per-halosubstituted C_6-C_{14} aryl, ~~up to per-halosubstituted C_7-C_{24} aralkyl, up to per-halosubstituted C_7-C_{24} alkaryl, and up to per-halosubstituted C_4-C_{23} alkheteroaryl~~.

38. (Canceled)

39. (Previously Presented) A compound as in claim 37 wherein the cyclic structures of B and L bound directly to D are substituted in the ortho position by hydrogen.

40. (Currently amended) A compound of claim 37 wherein B of Formula I is a substituted pyridyl, substituted quinolinyl or isoquinolinyl group substituted 1 to 3 times by 1 or more substituents which are each independently ~~selected from the group consisting of~~ -CN, halogen, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, -OH, up to per halo substituted C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkoxy or phenyl substituted by halogen up to per halo.

41. (Canceled)

42. (Currently amended) A compound of claim 37 wherein L^1 is additionally substituted 1 to 3 times by one or more substituents which are each, independently, ~~selected from the group consisting of~~ C_1-C_{10} alkyl, up to per halo substituted C_1-C_{10} alkyl, -CN, -OH, halogen, C_1-C_{10} alkoxy ~~and~~ or up to per halo substituted C_1-C_{10} alkoxy.

43 **(Canceled)**

44, **(Canceled)**

45. **(Currently amended)** A compound as in claim 37 wherein substituents for B and L and additional substituents for L^1, are each, independently, ~~selected from the group consisting of~~ C_1-C_{10} alkyl up to per halo substituted C_1-C_{10} alkyl, CN, OH, halogen, C_1-C_{10} alkoxy ~~and~~ or up to per halo ~~substituent~~ substituted C_1-C_{10} alkoxy.

46. **(Currently amended)** A compound of claim 37 which is a pharmaceutically acceptable salt of a compound of formula I which is ~~selected from the group consisting of~~

a) ~~basic salts of organic acids and inorganic acids selected from the group consisting of~~ a basic salt of an organic acid or inorganic acid which is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluorosulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid (tosylate salt), 1-napthalene sulfonic acid, 2-napthalene sulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, ~~and~~ or mandelic acid; and

b) ~~acid salts of organic and inorganic bases containing cations selected from the group consisting of alkaline cations, alkaline earth cations, the ammonium cation, aliphatic substituted ammonium cations and aromatic substituted ammonium cations~~ an acid salt of an organic or inorganic base containing a cation which is an alkaline cation, alkaline earth cation, the ammonium cation, an aliphatic substituted ammonium cation or an aromatic substituted ammonium cation.

47. **(Previously presented)** A pharmaceutical composition comprising a compound of claim 37 or a pharmaceutically acceptable salt of a compound of formula I, and a physiologically acceptable carrier.

48. **(Currently amended)** A method of inhibiting raf kinase in a host ~~for the treatment of solid cancers~~, comprising administering to a host in need thereof an effective amount of a compound of Formula I of claim 37.

49. **(Currently amended)** A compound as in claim 37 wherein R_x is NR_aR_b and R_a and R_b are each, independently, ~~selected from~~ hydrogen ~~and~~ or C_1 - C_{10} alkyl.